STAT+: Merck to acquire Imago, bolstering pipeline for drugs targeting bone marrow diseases

Merck said Monday that it is acquiring Imago BioSciences for $1.35 billion, adding experimental drugs that target bone marrow diseases to its research pipeline.

The all-cash deal values Imago at $36 per share, or a 107% premium from its closing price on Friday.

Continue to STAT+ to read the full story…